2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
    Neuronal Signaling
  4. TRP Channel
  5. TRPV6 Isoform
  6. TRPV6 Antagonist

TRPV6 Antagonist

TRPV6 Antagonists (3):

Cat. No. Product Name Effect Purity
  • HY-P1651
    SOR-C13
    		Antagonist 99.12%
    SOR-C13, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 has anticancer activity.
  • HY-P1651A
    SOR-C13 TFA
    		Antagonist 99.32%
    SOR-C13 TFA, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 TFA has anticancer activity.
  • HY-P1651B
    SOR-C13 acetate
    		Antagonist 99.11%
    SOR-C13 acetate is the acetate salt form of SOR-C13 (HY-P1651). SOR-C13 acetate is an antagonist for transient receptor potential vanilloid 6 (TRPV 6), with an IC50 of 14 nM. SOR-C13 acetate inhibits tumor growth in SKOV-3 xenograft mouse model.